Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results
Published on 12/17/2025 at 11:50 | Redaktion boerse-global.de
Shares of Gilead Sciences are consolidating near the $120 level following significant clinical and financial developments. The company announced that its investigational once-daily oral combination of bictegravir and lenacapavir successfully met the primary endpoint in the Phase 3 ARTISTRY-2 trial. This news has prompted several analyst upgrades and comes on the heels of a strong quarterly earnings report.
Gilead’s recent third-quarter results exceeded market expectations, posting earnings per share (EPS) of $2.47 against estimates of $2.16. Consequently, the company raised its full-year 2025 EPS guidance to a range of $8.05 to $8.25. The firm also maintains a robust dividend, with a payout of $0.79 per share scheduled for December 30, 2025, translating to a yield of approximately 2.6%.
Market Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
